Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The human secretome.

Uhlén M, Karlsson MJ, Hober A, Svensson AS, Scheffel J, Kotol D, Zhong W, Tebani A, Strandberg L, Edfors F, Sjöstedt E, Mulder J, Mardinoglu A, Berling A, Ekblad S, Dannemeyer M, Kanje S, Rockberg J, Lundqvist M, Malm M, Volk AL, Nilsson P, Månberg A, Dodig-Crnkovic T, Pin E, Zwahlen M, Oksvold P, von Feilitzen K, Häussler RS, Hong MG, Lindskog C, Ponten F, Katona B, Vuu J, Lindström E, Nielsen J, Robinson J, Ayoglu B, Mahdessian D, Sullivan D, Thul P, Danielsson F, Stadler C, Lundberg E, Bergström G, Gummesson A, Voldborg BG, Tegel H, Hober S, Forsström B, Schwenk JM, Fagerberg L, Sivertsson Å.

Sci Signal. 2019 Nov 26;12(609). pii: eaaz0274. doi: 10.1126/scisignal.aaz0274.

PMID:
31772123
2.

Multiplexed analysis of the secretin-like GPCR-RAMP interactome.

Lorenzen E, Dodig-Crnković T, Kotliar IB, Pin E, Ceraudo E, Vaughan RD, Uhlèn M, Huber T, Schwenk JM, Sakmar TP.

Sci Adv. 2019 Sep 18;5(9):eaaw2778. doi: 10.1126/sciadv.aaw2778. eCollection 2019 Sep.

3.

Array-Based Profiling of Proteins and Autoantibody Repertoires in CSF.

Pin E, Sjöberg R, Andersson E, Hellström C, Olofsson J, Jernbom Falk A, Bergström S, Remnestål J, Just D, Nilsson P, Månberg A.

Methods Mol Biol. 2019;2044:303-318. doi: 10.1007/978-1-4939-9706-0_19.

PMID:
31432421
4.

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Pin E, Stratton S, Belluco C, Liotta L, Nagle R, Hodge KA, Deng J, Dong T, Baldelli E, Petricoin E, Pierobon M.

Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.

5.

Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer.

Pin E, Henjes F, Hong MG, Wiklund F, Magnusson P, Bjartell A, Uhlén M, Nilsson P, Schwenk JM.

J Proteome Res. 2017 Jan 6;16(1):204-216. doi: 10.1021/acs.jproteome.6b00620. Epub 2016 Oct 24.

6.

Immunocapture strategies in translational proteomics.

Fredolini C, Byström S, Pin E, Edfors F, Tamburro D, Iglesias MJ, Häggmark A, Hong MG, Uhlen M, Nilsson P, Schwenk JM.

Expert Rev Proteomics. 2016;13(1):83-98. doi: 10.1586/14789450.2016.1111141. Epub 2015 Nov 11. Review.

7.

Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.

Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E.

J Proteome Res. 2014 Jun 6;13(6):2846-55. doi: 10.1021/pr401267m. Epub 2014 May 14.

PMID:
24787230
8.

Preparation and use of reverse protein microarrays.

Pin E, Federici G, Petricoin EF 3rd.

Curr Protoc Protein Sci. 2014 Feb 3;75:27.7.1-27.7.29. doi: 10.1002/0471140864.ps2707s75.

PMID:
24510676
9.

HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.

Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y, Giaccone G.

Oncogene. 2014 Oct 2;33(40):4867-76. doi: 10.1038/onc.2013.439. Epub 2013 Oct 28.

10.

Individualized therapy for metastatic colorectal cancer.

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C.

J Intern Med. 2013 Jul;274(1):1-24. doi: 10.1111/joim.12070. Epub 2013 Apr 12. Review.

11.

MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events.

Aretz S, Tricarico R, Papi L, Spier I, Pin E, Horpaopan S, Cordisco EL, Pedroni M, Stienen D, Gentile A, Panza A, Piepoli A, de Leon MP, Friedl W, Viel A, Genuardi M.

Eur J Hum Genet. 2014 Jul;22(7):923-9. doi: 10.1038/ejhg.2012.309. Epub 2013 Jan 30.

12.

The role of proteomics in prostate cancer research: biomarker discovery and validation.

Pin E, Fredolini C, Petricoin EF 3rd.

Clin Biochem. 2013 Apr;46(6):524-38. doi: 10.1016/j.clinbiochem.2012.12.012. Epub 2012 Dec 22. Review.

PMID:
23266295
13.

A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd.

J Thorac Oncol. 2012 Dec;7(12):1755-1766. doi: 10.1097/JTO.0b013e3182725fc7.

14.

Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability.

Ruggieri V, Pin E, Russo MT, Barone F, Degan P, Sanchez M, Quaia M, Minoprio A, Turco E, Mazzei F, Viel A, Bignami M.

Oncogene. 2013 Sep 19;32(38):4500-8. doi: 10.1038/onc.2012.479. Epub 2012 Oct 29.

PMID:
23108399
15.

MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated Polyposis.

Pin E, Pastrello C, Tricarico R, Papi L, Quaia M, Fornasarig M, Carnevali I, Oliani C, Fornasin A, Agostini M, Maestro R, Barana D, Aretz S, Genuardi M, Viel A.

Int J Cancer. 2013 Mar 1;132(5):1060-9. doi: 10.1002/ijc.27761. Epub 2012 Aug 28.

16.

Integrated analysis of unclassified variants in mismatch repair genes.

Pastrello C, Pin E, Marroni F, Bedin C, Fornasarig M, Tibiletti MG, Oliani C, Ponz de Leon M, Urso ED, Della Puppa L, Agostini M, Viel A.

Genet Med. 2011 Feb;13(2):115-24. doi: 10.1097/GIM.0b013e3182011489.

PMID:
21239990
17.

Somatic mosaicism in a patient with Lynch syndrome.

Pastrello C, Fornasarig M, Pin E, Berto E, Pivetta B, Viel A.

Am J Med Genet A. 2009 Feb;149A(2):212-5. doi: 10.1002/ajmg.a.32620.

PMID:
19133695
18.

Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.

Tedeschi R, Pin E, Martorelli D, Bidoli E, Marus A, Pratesi C, Bortolin MT, Zanussi S, Vaccher E, Dolcetti R, De Paoli P.

Clin Vaccine Immunol. 2007 Apr;14(4):435-41. Epub 2007 Feb 28.

19.

A follow-up study of 300 ex-clients of a drug-free narcotic treatment program in New York City.

Pin EJ, Martin JM, Walsh JF.

Am J Drug Alcohol Abuse. 1976;3(3):397-407.

PMID:
1032753

Supplemental Content

Support Center